10-Q quarterly report · filed Oct 29, 2026

Dexcom (DXCM) Q3 2026 10-Q Quarterly Report

Short answer

Dexcom (DXCM) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.3B (up 11.2% year over year) with net income of $275M.

Q3 2026 key financials · XBRL

Revenue
$1.3B
+11.2% YoY · +2.8% QoQ
Net income
$275M
−3.1% YoY · +10.4% QoQ
Operating margin
24.3%
Gross margin
64.3%
EPS (diluted)
$0.72
+1.4% YoY · +12.5% QoQ

Source: XBRL data from the Dexcom (DXCM) Q3 2026 10-Q on SEC EDGAR. USD.

Dexcom Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $1,344.5M, up $135.2M or 11% YoY, driven by disposable sensor volume
  • Gross margin 64.3% vs 60.5% YoY, supported by G7 15 Day and manufacturing efficiencies
  • Operating income $327.2M, up 35% YoY; operating margin 24.3% vs 20.1%
  • Cash $1.82B, down $180.8M from December 31, 2025; nine-month operating cash flow $1.12B
  • Share repurchases drove $1,023.8M financing cash use; significant manufacturing capital expenditures expected next year

Risk Factors

  • New shareholder-return risk: October 2026 authorization of $1.00 billion 2027 Share Repurchase Program
  • Most material update: Repurchases may not enhance share price or earnings per share
  • Market risk: Repurchase timing could expose Dexcom to unfavorable market conditions and price volatility
  • Financial risk: Share buybacks depend on availability of funds and competing strategic opportunities

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Dexcom quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.